Compare · GILD vs QNCX
GILD vs QNCX
Side-by-side comparison of Gilead Sciences Inc. (GILD) and Quince Therapeutics Inc. (QNCX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both GILD and QNCX operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- GILD is the larger of the two at $155.82B, about 9854.5x QNCX ($15.8M).
- Over the past year, GILD is up 10.9% and QNCX is down 92.1% - GILD leads by 103.0 points.
- GILD has been more active in the news (20 items in the past 4 weeks vs 6 for QNCX).
- GILD has more recent analyst coverage (25 ratings vs 3 for QNCX).
- Company
- Gilead Sciences Inc.
- Quince Therapeutics Inc.
- Price
- $122.11-2.67%
- $0.94-5.18%
- Market cap
- $155.82B
- $15.8M
- 1M return
- -8.61%
- -24.76%
- 1Y return
- +10.88%
- -92.10%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 1992
- 2019
- News (4w)
- 20
- 6
- Recent ratings
- 25
- 3
Gilead Sciences Inc.
Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of human immunodeficiency virus (HIV) infection; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr; Tizona; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos; Janssen; Japan Tobacco, Inc.; Gadeta; Bristol-Myers Squibb Company; Merck; and Novo Nordisk A/S. The company was founded in 1987 and is headquartered in Foster City, California.
Latest GILD
- Merck and Gilead Provide Update on Phase 3 KEYNOTE-D46/EVOKE-03 Study
- Gilead Applauds Collaborative Efforts to Launch Lenacapavir for HIV Prevention in South Africa
- GILEAD SCIENCES AND LAKEFRONT COMPLETE ACQUISITION OF OURO MEDICINES TO FURTHER EXPAND INFLAMMATION PIPELINE
- Gilead Sciences and Lakefront Complete Acquisition of Ouro Medicines to Further Expand Inflammation Pipeline
- Chairman & CEO O'Day Daniel Patrick sold $1,971,847 worth of shares (15,000 units at $131.46) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 617,567 units (SEC Form 4)
- Gilead's Livdelzi® (Seladelpar) Delivers Statistically Significant Composite ALP Normalization in Phase 3 IDEAL Trial in Primary Biliary Cholangitis (PBC)
- Phase 3 ASSURE Interim Data: Majority of People in the Study with ALP 1–1.67×ULN Achieved High and Sustained Composite ALP Normalization at 24 Months with Gilead's Livdelzi (Seladelpar)
- FDA Approval for HEPCLUDEX issued to GILEAD SCIENCES INC
- FDA Grants Accelerated Approval to Gilead's Hepcludex® (bulevirtide-gmod), the First and Only Approved Treatment for Chronic Hepatitis Delta Virus (HDV)
- Gilead Receives CHMP Positive Opinion for Trodelvy® in First-Line Metastatic Triple-Negative Breast Cancer for Patients Not Candidates for PD-(L)1 Inhibitors
Latest QNCX
- SEC Form 8-K filed by Quince Therapeutics Inc.
- Amendment: Quince Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure
- UPDATE - Quince Therapeutics Announces Clinically Meaningful Improvements Across Functional, Hemodynamic and Biomarker Measures in Phase 2 Study in PAH and PH-ILD
- Quince Therapeutics Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Statements and Exhibits
- Quince Announces Acquisition of Orphai and up to $187 Million Private Placement to Advance Pulmonary Pipeline
- Quince Therapeutics Announces Clinically Meaningful Improvements Across Functional, Hemodynamic and Biomarker Measures in Phase 2 Study in PAH and PH-ILD
- Amendment: SEC Form SCHEDULE 13G/A filed by Quince Therapeutics Inc.
- SEC Form 10-Q filed by Quince Therapeutics Inc.
- SEC Form 8-K filed by Quince Therapeutics Inc.
- SEC Form DEFA14A filed by Quince Therapeutics Inc.